Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 4516 AL 4530

Do glutathione and copper interact to modify Alzheimer's disease pathogenesis?

Ho T, Ahmadi S, Kerman K.

Free Radic Biol Med. 2022 Mar;181:180-196. doi: 10.1016/j.freeradbiomed.2022.01.025. Epub 2022 Jan 29.

Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels

Li XT.

Metab Brain Dis. 2022 Mar;37(3):581-587. doi: 10.1007/s11011-022-00921-w. Epub 2022 Jan 31.

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

Gonzales MM, Garbarino VR, Marques Zilli E, Petersen RC, Kirkland JL, Tchkonia T, Musi N, Seshadri S, Craft S, Orr ME.

J Prev Alzheimers Dis. 2022;9(1):22-29. doi: 10.14283/jpad.2021.62.

Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis

Wang H, Zong Y, Han Y, Zhao J, Liu H, Liu Y.

Expert Opin Drug Saf. 2022 Mar;21(3):407-415. doi: 10.1080/14740338.2022.2027905. Epub 2022 Jan 31.

Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review

Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F.

JAMA Neurol. 2022 Mar 1;79(3):291-304. doi: 10.1001/jamaneurol.2021.5205.

Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial

Vila-Castelar C, Tariot PN, Sink KM, Clayton D, Langbaum JB, Thomas RG, Chen Y, Su Y, Chen K, Hu N, Giraldo-Chica M, Tobón C, Acosta-Baena N, Luna E, Londoño M, Ospina P, Tirado V, Muñoz C, Henao E, Bocanegra Y, Alvarez S, Rios-Romenets S, Ghisays V, Goradia D, Lee W, Luo J, Malek-Ahmadi MH, Protas HD, Lopera F, Reiman EM, Quiroz YT; API ADAD Colombia Trial Group.

Alzheimers Dement. 2022 Nov;18(11):2272-2282. doi: 10.1002/alz.12552. Epub 2022 Feb 1.

Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs

Reiman EM, Mattke S, Kordower JH, Khachaturian ZS, Khachaturian AS.

Alzheimers Dement. 2022 Jan;18(1):7-9. doi: 10.1002/alz.12533. Epub 2022 Feb 1.

The calcium-free form of atorvastatin inhibits amyloid-β(1-42) aggregation in vitro

Nedaei H, Rezaei-Ghaleh N, Giller K, Becker S, Karami L, Moosavi-Movahedi AA, Griesinger C, Saboury AA.

J Biol Chem. 2022 Mar;298(3):101662. doi: 10.1016/j.jbc.2022.101662. Epub 2022 Jan 30.

Remote Ischemic Conditioning: A Potential Treatment for Chronic Cerebral Hypoperfusion

Ma X, Ji C.

Eur Neurol. 2022;85(4):253-259. doi: 10.1159/000521803. Epub 2022 Feb 1.

Human iPSC-Derived Neural Models for Studying Alzheimer's Disease: from Neural Stem Cells to Cerebral Organoids

Barak M, Fedorova V, Pospisilova V, Raska J, Vochyanova S, Sedmik J, Hribkova H, Klimova H, Vanova T, Bohaciakova D.

Stem Cell Rev Rep. 2022 Feb;18(2):792-820. doi: 10.1007/s12015-021-10254-3. Epub 2022 Feb 2.

An autopsy case of Alzheimer's disease with amygdala-predominant Lewy pathology presenting with frontotemporal dementia-like psychiatric symptoms

Beck G, Shigenobu K, Ukon K, Yamashita R, Yonenobu Y, Morii E, Hasegawa M, Ikeda M, Murayama S, Mochizuki H.

Neuropathology. 2022 Apr;42(2):147-154. doi: 10.1111/neup.12786. Epub 2022 Feb 2.

Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease

Taliyan R, Kakoty V, Sarathlal KC, Kharavtekar SS, Karennanavar CR, Choudhary YK, Singhvi G, Riadi Y, Dubey SK, Kesharwani P.

J Control Release. 2022 Mar;343:528-550. doi: 10.1016/j.jconrel.2022.01.044. Epub 2022 Jan 31.

Physiology and pharmacology of amyloid precursor protein

Cho Y, Bae HG, Okun E, Arumugam TV, Jo DG.

Pharmacol Ther. 2022 Jul;235:108122. doi: 10.1016/j.pharmthera.2022.108122. Epub 2022 Feb 1.

A systematic review and meta-analysis of transcranial direct-current stimulation effects on cognitive function in patients with Alzheimer's disease

Majdi A, van Boekholdt L, Sadigh-Eteghad S, Mc Laughlin M.

Mol Psychiatry. 2022 Apr;27(4):2000-2009. doi: 10.1038/s41380-022-01444-7. Epub 2022 Feb 3.

Variant TREM2 Signaling in Alzheimer's Disease

Olufunmilayo EO, Holsinger RMD.

J Mol Biol. 2022 Apr 15;434(7):167470. doi: 10.1016/j.jmb.2022.167470. Epub 2022 Feb 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias